DOI QR코드

DOI QR Code

Updated treatment strategies for intestinal Behçet's disease

  • Park, Yong Eun (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Cheon, Jae Hee (Department of Internal Medicine, Yonsei University College of Medicine)
  • 투고 : 2017.11.17
  • 심사 : 2017.11.20
  • 발행 : 2018.01.01

초록

Behçet disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor ${\alpha}$ are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation of Korea, Yonsei University College of Medicine

참고문헌

  1. Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behcet's disease. Intest Res 2017;15:318-327. https://doi.org/10.5217/ir.2017.15.3.318
  2. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. Curr Opin Rheumatol 2015;27:24-31. https://doi.org/10.1097/BOR.0000000000000125
  3. Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behcet's disease. Intest Res 2017;15:311-317. https://doi.org/10.5217/ir.2017.15.3.311
  4. Kim DH, Cheon JH. Intestinal Behcet's disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J 2016;57:22-32. https://doi.org/10.3349/ymj.2016.57.1.22
  5. Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet's disease. Yonsei Med J 2013;54:1084-1090. https://doi.org/10.3349/ymj.2013.54.5.1084
  6. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013;58:496-503. https://doi.org/10.1007/s10620-012-2351-9
  7. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol 2000;30:144-154. https://doi.org/10.1097/00004836-200003000-00006
  8. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal Behcet disease. Gastroenterol Hepatol (N Y) 2012;8:103-112.
  9. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and longterm clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:1594-1602. https://doi.org/10.1002/ibd.21517
  10. Baek SJ, Kim CW, Cho MS, et al. Surgical treatment and outcomes in patients with intestinal Behcet disease: long-term experience of a single large-volume center. Dis Colon Rectum 2015;58:575-581. https://doi.org/10.1097/DCR.0000000000000373
  11. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008;67:1656-1662. https://doi.org/10.1136/ard.2007.080432
  12. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol 2007;42:737-745. https://doi.org/10.1007/s00535-007-2090-4
  13. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-$TNF{\alpha}$ monoclonal antibodies. J Gastroenterol 2014;49:156-162. https://doi.org/10.1007/s00535-013-0872-4
  14. Lee HW, Kim WH, Cheon JH. The medical treatments of intestinal Behcet's disease: an update. Intest Res 2013;11:155-160. https://doi.org/10.5217/ir.2013.11.3.155
  15. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2016;7:CD008870.
  16. Yoo HM, Han KH, Kim PS, et al. Clinical features of intestinal Behet's disease and therapeutic effects of sulfasalazine. Korean J Gastroenterol 1997;29:465-472.
  17. Matsukawa M, Yamasaki T, Kouda T, Kurihara M. Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behcet's disease, and simple ulcers. J Gastroenterol 2001;36:255-258. https://doi.org/10.1007/s005350170112
  18. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Longterm clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38-e45. https://doi.org/10.1097/MCG.0b013e3182431d56
  19. Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome: a strobecompliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore) 2016;95:e3348. https://doi.org/10.1097/MD.0000000000003348
  20. Nakase H, Okazaki K, Kawanami C, et al. Therapeutic effects on intestinal Behcet's disease of an intravenous drug delivery system using dexamethasone incorporated in lipid emulsion. J Gastroenterol Hepatol 2001;16:1306-1308. https://doi.org/10.1046/j.1440-1746.2001.02510.x
  21. Toda K, Shiratori Y, Yasuda M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behcet's disease. J Gastroenterol 2002;37:844-848. https://doi.org/10.1007/s005350200139
  22. Yasuo M, Miyabayashi H, Okano T, Aoki H, Ichikawa K, Hirose Y. Successful treatment with corticosteroid in a case of Behcet's syndrome with multiple esophageal ulcerations. Intern Med 2003;42:696-699. https://doi.org/10.2169/internalmedicine.42.696
  23. Park JJ, Cheon JH, Moon CM, et al. W1321 long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behcet's disease. Gastroenterology 2010;138(5 Suppl 1):S698-S699.
  24. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000;43:692-700. https://doi.org/10.1007/BF02235590
  25. Lee HW, Cheon JH, Lee HJ, et al. Postoperative effects of thiopurines in patients with intestinal Behcet's disease. Dig Dis Sci 2015;60:3721-3727. https://doi.org/10.1007/s10620-015-3799-1
  26. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012;18:750-757. https://doi.org/10.1002/ibd.21757
  27. Park MS, Kim DH, Kim DH, et al. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci 2015;60:195-204. https://doi.org/10.1007/s10620-014-3355-4
  28. Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflamm Bowel Dis 2010;16:188-189. https://doi.org/10.1002/ibd.20970
  29. Cantarini L, Stromillo ML, Vitale A, et al. Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's disease with different organ involvement: a case series. Isr Med Assoc J 2016;18:238-242.
  30. Beales IL. Gastrointestinal involvement in Behcet's syndrome. Am J Gastroenterol 1998;93:2633.
  31. Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenileonset Behcet disease. Inflamm Bowel Dis 2008;14:396-400. https://doi.org/10.1002/ibd.20317
  32. Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease. Ann Pharmacother 2004;38:808-811. https://doi.org/10.1345/aph.1D524
  33. Lee HJ, Cheon JH, Lee KJ, et al. Clinical experience of thalidomide in the treatment of Korean patients with intestinal Behcet's disease: pilot experience in a single center. Intest Res 2010;8:63-69. https://doi.org/10.5217/ir.2010.8.1.63
  34. Sonta T, Araki Y, Koubokawa M, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease. J Clin Gastroenterol 2000;30:195-199. https://doi.org/10.1097/00004836-200003000-00013
  35. Saleh Z, Arayssi T. Update on the therapy of Behcet disease. Ther Adv Chronic Dis 2014;5:112-134. https://doi.org/10.1177/2040622314523062
  36. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's disease. Semin Arthritis Rheum 1998;27:197-217. https://doi.org/10.1016/S0049-0172(98)80001-2
  37. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999;341:1284-1291. https://doi.org/10.1056/NEJM199910213411707
  38. Lopalco G, Rigante D, Venerito V, et al. Update on the medical management of gastrointestinal Behcet's disease. Mediators Inflamm 2017;2017:1460491.
  39. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014;4:e004587. https://doi.org/10.1136/bmjopen-2013-004587
  40. Park J, Cheon JH, Park YE, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet's disease. Int J Colorectal Dis 2017;32:745-751. https://doi.org/10.1007/s00384-016-2728-x
  41. Sharara AI. When to start immunomodulators in inflammatory bowel disease? Dig Dis 2016;34:125-131. https://doi.org/10.1159/000443127
  42. Kim B, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Overlooked management and risk factors for anemia in patients with intestinal Behcet's disease in actual clinical practice. Gut Liver 2015;9:750-5. https://doi.org/10.5009/gnl14193
  43. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 2017;153:827-834. https://doi.org/10.1053/j.gastro.2017.07.032
  44. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-${\alpha}$ antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011;21:184-191. https://doi.org/10.3109/s10165-010-0370-y
  45. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:1833-1838.
  46. Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res 2017;15:395-401. https://doi.org/10.5217/ir.2017.15.3.395
  47. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. https://doi.org/10.1097/MD.0000000000003863
  48. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015;13:940-948. https://doi.org/10.1016/j.cgh.2014.08.042
  49. Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014;69:735-739. https://doi.org/10.1007/s12013-014-9860-4
  50. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol 2015;34:1293-1301. https://doi.org/10.1007/s10067-013-2443-8
  51. Vitale A, Rigante D, Caso F, et al. Inhibition of interleu-kin-1 by canakinumab as a successful monodrug strategy for the treatment of refractory Behcet's disease: a case series. Dermatology 2014;228:211-214. https://doi.org/10.1159/000358125
  52. Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet's disease: four cases and literature review. Semin Arthritis Rheum 2016;45:733-737. https://doi.org/10.1016/j.semarthrit.2015.11.012
  53. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroen-terology 2001;120:995-999. https://doi.org/10.1053/gast.2001.22556
  54. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008;14:1259-1264. https://doi.org/10.1002/ibd.20457
  55. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-728. https://doi.org/10.1136/gut.49.5.725
  56. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet's disease: report of a case. Dis Colon Rectum 2007;50:672-676. https://doi.org/10.1007/s10350-006-0813-x
  57. Tanida S, Mizoshita T, Nishie H, et al. Long-term efficacy of adalimumab in patients with intestinal Behcet's disease: eight consecutive cases. J Clin Med Res 2016;8:334-337. https://doi.org/10.14740/jocmr2477w
  58. De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. J Crohns Colitis 2011;5:364-368. https://doi.org/10.1016/j.crohns.2011.03.006
  59. Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 2017;36:451-455. https://doi.org/10.1007/s10067-016-3417-4
  60. Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol 2016;35:1281-1286. https://doi.org/10.1007/s10067-015-3004-0
  61. Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy. Report of a case. Dis Colon Rectum 2003;46:118-121. https://doi.org/10.1007/s10350-004-6506-4
  62. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behcet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008;46:212-215. https://doi.org/10.1097/MPG.0b013e3181346b60
  63. Maruyama Y, Hisamatsu T, Matsuoka K, et al. A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012;51:2125-2129. https://doi.org/10.2169/internalmedicine.51.8005
  64. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013;52:1855-1862. https://doi.org/10.2169/internalmedicine.52.0589
  65. Ideguchi H, Suda A, Takeno M, et al. Gastrointestinal manifestations of Behcet's disease in Japan: a study of 43 patients. Rheumatol Int 2014;34:851-856. https://doi.org/10.1007/s00296-013-2838-5
  66. Shimizu Y, Takeda T, Matsumoto R, et al. Clinical efficacy of adalimumab for a postoperative marginal ulcer in gas-trointestinal Behcet disease. Nihon Shokakibyo Gakkai Zasshi 2012;109:774-780.
  67. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-27. https://doi.org/10.3904/kjim.2007.22.1.24
  68. Matsuoka K, Saito E, Fujii T, et al. Tacrolimus for the treatment of ulcerative colitis. Intest Res 2015;13:219-226. https://doi.org/10.5217/ir.2015.13.3.219
  69. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267. https://doi.org/10.1098/rspb.1957.0048
  70. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized place-bo-controlled and double-blind study. Arch Dermatol 2002;138:467-471.
  71. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-335. https://doi.org/10.1016/j.semarthrit.2003.09.010
  72. Zouboulis CC, Orfanos CE. Treatment of Adamantia-des-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-1016.
  73. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335-336. https://doi.org/10.1007/BF00407749
  74. Grimbacher B, Wenger B, Deibert P, Ness T, Koetter I, Pe-ter HH. Loss of vision and diarrhoea. Lancet 1997;350:1818. https://doi.org/10.1016/S0140-6736(97)10114-3
  75. Monastirli A, Chroni E, Georgiou S, et al. Interferon-${\alpha}$ treatment for acute myelitis and intestinal involvement in severe Behcet's disease. QJM 2010;103:787-790. https://doi.org/10.1093/qjmed/hcq125
  76. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000;47:119-125. https://doi.org/10.1016/S0162-3109(00)00192-2
  77. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 2002;105:301-312. https://doi.org/10.1023/A:1021227019915
  78. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241-243. https://doi.org/10.1136/bjo.76.4.241
  79. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008;28:765-778. https://doi.org/10.1016/j.iac.2008.06.002
  80. Shek LP, Lee YS, Lee BW, Lehman TJ. Thalidomide responsiveness in an infant with Behcet's syndrome. Pediatrics 1999;103(6 Pt 1):1295-1297. https://doi.org/10.1542/peds.103.6.1295
  81. Kari JA, Shah V, Dillon MJ. Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 2001;40:933-938. https://doi.org/10.1093/rheumatology/40.8.933
  82. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680. https://doi.org/10.1084/jem.177.6.1675
  83. Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol 2015;33(6 Suppl 94):S129-S137.
  84. Atas H, Cemil BC, Canpolat F, Gonul M. The effect of colchicine on mean platelet volume in Behcet's disease. Ann Clin Lab Sci 2015;45:545-549.
  85. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001;44:2686-2692. https://doi.org/10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H
  86. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399-402.
  87. Hatemi G, Silman A, Bang D, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009;68:1528-1534. https://doi.org/10.1136/ard.2008.087957
  88. Soysal T, Salihoglu A, Esatoglu SN, et al. Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology (Oxford) 2014;53:1136-1141. https://doi.org/10.1093/rheumatology/ket479
  89. Yamato K. Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behcet disease. Int J Hematol 2003;77:82-85. https://doi.org/10.1007/BF02982607
  90. Rossi G, Moretta A, Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 2004;103:748-750. https://doi.org/10.1182/blood-2003-10-3617
  91. Namba K, Sonoda KH, Kitamei H, et al. Granulocytapheresis in patients with refractory ocular Behcet's disease. J Clin Apher 2006;21:121-128. https://doi.org/10.1002/jca.20076
  92. Gul A. Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(5 Suppl 24):S6-S12.
  93. Lee CK, Kim HJ. Pathogenesis and treatment of intestinal Behcet's disease. Korean J Gastroenterol 2007;50:3-8.
  94. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun 2015;62:67-74. https://doi.org/10.1016/j.jaut.2015.06.005
  95. Kimura M, Tsuji Y, Iwai M, et al. Usefulness of adalimumab for treating a case of intestinal Behcet's disease with trisomy 8 myelodysplastic syndrome. Intest Res 2015;13:166-169. https://doi.org/10.5217/ir.2015.13.2.166
  96. Ishioka M, Onochi K, Suzuki Y, et al. Successful treatment with infliximab for refractory paraileostomal ulceration in a patient with Behcet's disease. Clin J Gastroenterol 2015;8:193-196. https://doi.org/10.1007/s12328-015-0576-9
  97. Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet's disease treated with infliximab. Dig Dis Sci 2017;62:441-447. https://doi.org/10.1007/s10620-016-4395-8
  98. Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behcet's disease refractory to conventional therapy? Intest Res 2017;15:263-265. https://doi.org/10.5217/ir.2017.15.3.263
  99. Wu KC, Ran ZH, Gao X, et al. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intest Res 2016;14:152-163. https://doi.org/10.5217/ir.2016.14.2.152
  100. Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2007;3:99-105. https://doi.org/10.2147/tcrm.2007.3.1.99
  101. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenileonset Behcets disease. Int J Immunopathol Pharmacol 2009;22:551-555. https://doi.org/10.1177/039463200902200235
  102. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, place-bo-controlled trial. Gastroenterology 2001;121:1088-1094. https://doi.org/10.1053/gast.2001.28674
  103. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785. https://doi.org/10.1016/S0016-5085(03)00382-2
  104. O'Toole A, Lucci M, Korzenik J. Inflammatory bowel dis-ease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA. Dig Dis Sci 2016;61:1772-1774. https://doi.org/10.1007/s10620-015-4007-z
  105. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;(1):CD005121.
  106. Zou J, Guan JL. Interleukin-1-related genes polymorphisms in Turkish patients with Behcet disease: a meta-analysis. Mod Rheumatol 2014;24:321-326. https://doi.org/10.3109/14397595.2013.844304
  107. Koryurek OM, Kalkan G. A new alternative therapy in dermatology: tocilizumab. Cutan Ocul Toxicol 2016;35:145-152.
  108. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002;31:205-210. https://doi.org/10.1080/030097402320318387
  109. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 2017;38:127-142. https://doi.org/10.1016/j.tips.2016.10.014
  110. Danese S, Vermeire S, Hellstern P, et al. 764 Results of andante, a randomized clinical study with an anti-IL6 an-tibody (PF-04236921) in subjects with Crohn's disease who are anti-TNF inadequate responders. Gastroenterology 2016;150(4 Suppl 1):S155.
  111. Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 2014;9:e114195. https://doi.org/10.1371/journal.pone.0114195
  112. Yazici Y, Yurdakul S, Yazici H. Behcet's syndrome. Curr Rheumatol Rep 2010;12:429-435. https://doi.org/10.1007/s11926-010-0132-z
  113. Yi SW, Cheon JH, Kim JH, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease: a single center experience in Korea. J Korean Med Sci 2009;24:52-56. https://doi.org/10.3346/jkms.2009.24.1.52

피인용 문헌

  1. 건선 치료용 한약제제에 대한 임상시험 가이드라인 설명 및 제언 vol.31, pp.2, 2018, https://doi.org/10.6114/jkood.2018.31.2.040
  2. Update on the treatment of Behçet’s syndrome vol.14, pp.5, 2019, https://doi.org/10.1007/s11739-019-02035-1
  3. A Case of Henoch-Schönlein Purpura with Fulminant Complications and Its Long-term Outcome vol.23, pp.2, 2019, https://doi.org/10.3339/jkspn.2019.23.2.128
  4. Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet’s disease vol.9, pp.1, 2018, https://doi.org/10.1038/s41598-019-48291-1
  5. Is fasting beneficial for hospitalized patients with inflammatory bowel diseases? vol.18, pp.1, 2018, https://doi.org/10.5217/ir.2019.00055
  6. Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease vol.79, pp.7, 2018, https://doi.org/10.1007/s00393-020-00816-0
  7. Safety of systemic treatments for Behçet’s syndrome vol.19, pp.10, 2018, https://doi.org/10.1080/14740338.2020.1817379
  8. Development and Application of Advance Care Planning Workbooks to Facilitate Communication with Children and Adolescent Patients: A Pilot Test vol.23, pp.4, 2018, https://doi.org/10.14475/kjhpc.2020.23.4.212
  9. Esophageal Involvement of Behcet’s Disease vol.76, pp.6, 2018, https://doi.org/10.4166/kjg.2020.149
  10. Experimental Therapeutic Solutions for Behcet’s Disease vol.13, pp.None, 2018, https://doi.org/10.2147/jep.s265645
  11. Behçet Disease: An Update for Dermatologists vol.22, pp.4, 2018, https://doi.org/10.1007/s40257-021-00609-4
  12. Behcet’s Disease: An In-Depth Review about Pathogenesis, Gastrointestinal Manifestations, and Management vol.6, pp.4, 2018, https://doi.org/10.1159/000520696